Short-Dated Bullish Options Flow in Regeneron (REGN) Following 3Q Earnings Beat -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Regeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... MoreRegeneron (REGN) Tops Q3 EPS by 14c, Beats on Revenues
November 8, 2017 6:36 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $3.99, $0.14 better than the analyst estimate of $3.85. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.46 billion.
Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016Third... MoreRegeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial Program at AHA
November 7, 2017 8:26 AM ESTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the American Heart Association (AHA) Scientific Sessions 2017, November 11-15, in Anaheim, CA.
New analyses from the ODYSSEY ESCAPE trial evaluating treatment... More
